156 related articles for article (PubMed ID: 37149142)
1. Naloxone analogy and opioid overdose terminology preferences among rural caregivers: Differences by race.
Hosea K; Mashburn P; Kennelty K; Westrick SC; Look K; Evon D; Carpenter DM
J Am Pharm Assoc (2003); 2023; 63(5):1521-1529.e3. PubMed ID: 37149142
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
3. An exploratory study of a hands-on naloxone training for rural clinicians and staff.
Cody SL; Hines CB; Glenn CJ; Sharp-Marbury R; Newman S
J Nurs Scholarsh; 2023 May; 55(3):599-604. PubMed ID: 36411494
[TBL] [Abstract][Full Text] [Related]
4. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
[TBL] [Abstract][Full Text] [Related]
5. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders.
Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J
Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213
[TBL] [Abstract][Full Text] [Related]
6. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
7. Disparities in opioid overdose survival and naloxone administration in Pennsylvania.
Holmes LM; Rishworth A; King BH
Drug Alcohol Depend; 2022 Sep; 238():109555. PubMed ID: 35810621
[TBL] [Abstract][Full Text] [Related]
8. Take-home Naloxone at Opioid Treatment Programs: A Lifesaver.
Katzman JG; Bhatt S; Comerci GD
J Addict Med; 2022 Nov-Dec 01; 16(6):619-621. PubMed ID: 35220332
[TBL] [Abstract][Full Text] [Related]
9. Preliminary effectiveness of online opioid overdose and naloxone administration training and impact of naloxone possession on opioid use.
Sisson ML; Azuero A; Chichester KR; Carpenter MJ; Businelle MS; Shelton RC; Cropsey KL
Drug Alcohol Depend; 2023 Aug; 249():110815. PubMed ID: 37336007
[TBL] [Abstract][Full Text] [Related]
10. How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.
Lai Joyce Chun K; Olsen A; Taing MW; Clavarino A; Hollingworth S; Dwyer R; Middleton M; Nielsen S
Res Social Adm Pharm; 2019 Aug; 15(8):1014-1020. PubMed ID: 30926251
[TBL] [Abstract][Full Text] [Related]
11. Naloxone for Opioid Overdose: Comment.
Milas BL; Varon AJ
Anesthesiology; 2024 Apr; 140(4):857. PubMed ID: 38335038
[No Abstract] [Full Text] [Related]
12. Naloxone for Opioid Overdose: Comment.
Pattullo GG
Anesthesiology; 2024 Apr; 140(4):856. PubMed ID: 38335034
[No Abstract] [Full Text] [Related]
13. Opioid overdose prevention education in Texas during the COVID-19 pandemic.
Mathias CW; Cavazos DM; McGlothen-Bell K; Crawford AD; Flowers-Joseph B; Wang Z; Cleveland LM
Harm Reduct J; 2023 Mar; 20(1):37. PubMed ID: 36964600
[TBL] [Abstract][Full Text] [Related]
14. Assessing pharmacists' knowledge, attitudes, and practices of opioid management within different patient populations.
Martin SE; Hughes TD; Roller J; Ferreri SP
J Am Pharm Assoc (2003); 2024; 64(2):414-421.e1. PubMed ID: 38049067
[TBL] [Abstract][Full Text] [Related]
15. Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Kumar A; Linas BP; Morgan JR; Murphy SM; Walley AY; Yan S; Schackman BR; Marshall BDL
Addiction; 2022 May; 117(5):1372-1381. PubMed ID: 34825427
[TBL] [Abstract][Full Text] [Related]
16. Personal experience and awareness of opioid overdose occurrence among peers and willingness to administer naloxone in South Africa: findings from a three-city pilot survey of homeless people who use drugs.
Wilson M; Brumwell A; Stowe MJ; Shelly S; Scheibe A
Harm Reduct J; 2022 Feb; 19(1):17. PubMed ID: 35148779
[TBL] [Abstract][Full Text] [Related]
17. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
18. Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose.
Weiner SG; Carroll AD; Brisbon NM; Rodriguez CP; Covahey C; Stringfellow EJ; DiGennaro C; Jalali MS; Wakeman SE
J Subst Abuse Treat; 2022 Aug; 139():108785. PubMed ID: 35537918
[TBL] [Abstract][Full Text] [Related]
19. Considerations for the design of overdose education and naloxone distribution interventions: results of a multi-stakeholder workshop.
Sellen K; Markowitz B; Parsons JA; Leece P; Handford C; Goso N; Hopkins S; Klaiman M; Shahin R; Milos G; Wright A; Charles M; Morrison L; Strike C; Orkin A;
BMC Public Health; 2023 May; 23(1):888. PubMed ID: 37189052
[TBL] [Abstract][Full Text] [Related]
20. "A Blessing and a Curse:" Opioid Users' Perspectives on Naloxone and the Epidemic of Opioid Overdose.
Kline A; Mattern D; Cooperman N; Dooley-Budsock P; Williams JM; Borys S
Subst Use Misuse; 2020; 55(8):1280-1287. PubMed ID: 32182153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
